Efficacy in Advanced aRCC
Maximum $25 co-pay for eligible commercial patients*
The Afinitor Co-pay Card limits a co-pay for your eligible patients
- Insured patients pay a maximum co-pay of $25 each month for Afinitor
- Novartis Pharmaceuticals Corporation pays the remaining co-pay, up to $1200 per month
Start a patient today
- Prescribe once-daily Afinitor
- Print co-pay card
- Use a 7-day sample to get your patient started
* The Afinitor $25 Co-pay Card is not valid for prescriptions for which payment may be made in whole or in part under federal or state healthcare programs, including, but not limited to, Medicare, or Medicaid, or for residents in Massachusetts. This program will expire December 31, 2012.
Important Safety Information
Laboratory Abnormalities: The most common laboratory abnormalities (incidence ≥ 50%, all grades) were: decreased hemoglobin (92%) and lymphocytes (51%); increased cholesterol (77%), triglycerides (73%), glucose (57%) and creatinine (50%). The most common Grade 3/4 laboratory abnormalities (incidence ≥ 5%) were: decreased hemoglobin (13%), lymphocytes (18%), and phosphate (6%); and increased glucose (16%).
Please see additional Important Safety Information at the bottom of this page.
Please see full Prescribing Information.
ADVANCED RENAL CELL CARCINOMA (aRCC)
AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.
Important Safety Information
There have been reports of non-infectious pneumonitis, infections and kidney failure (including acute renal failure) in patients taking AFINITOR, some with fatal outcomes. Oral ulceration is the most frequently occurring adverse event and occurred in 44% of AFINITOR-treated patients. Most were Grade 1 or 2. Elevations of serum creatinine, proteinuria, glucose, lipids, and triglycerides and reductions of hemoglobin, lymphocytes, neutrophils, and platelets have also been reported.
Please see additional
